title: Seeking New Approaches to Patients With Small Cell Lung Cancer.
abstract: The fundamental approach to the treatment of small cell lung cancer (SCLC) has not changed in the last several decades, with most advances being restricted to improved radiation approaches. The standard first-line chemotherapy regimen in the United States and Europe remains cisplatin or carboplatin plus etoposide in the treatment of limited stage (LS-SCLC) and extensive stage (ES-SCLC) disease. Radiation therapy is administered to those patients with LS-SCLC, whose cancer is confined to the chest in a single tolerable radiation field. This article will summarize a number of exciting observations regarding the biology of SCLC and how a deeper understanding of newly integrated targets and target pathways may lead to new and better therapeutic approaches in the near future.
authors.affiliation: From the Merck Research Laboratories, Rahway, NJ; Department of Oncology, HFR Fribourg, Fribourg, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Winship Cancer Institute of Emory University, Atlanta, GA.
authors.forename: Marie Catherine
authors.initials: MC
authors.lastname: Pietanza
authors.affiliation: From the Merck Research Laboratories, Rahway, NJ; Department of Oncology, HFR Fribourg, Fribourg, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Winship Cancer Institute of Emory University, Atlanta, GA.
authors.forename: Stefan
authors.initials: S
authors.lastname: Zimmerman
authors.affiliation: From the Merck Research Laboratories, Rahway, NJ; Department of Oncology, HFR Fribourg, Fribourg, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Winship Cancer Institute of Emory University, Atlanta, GA.
authors.forename: Solange
authors.initials: S
authors.lastname: Peters
authors.affiliation: From the Merck Research Laboratories, Rahway, NJ; Department of Oncology, HFR Fribourg, Fribourg, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Winship Cancer Institute of Emory University, Atlanta, GA.
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Curran
mesh_terms: D064127:Aurora Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D003131:Combined Modality Therapy; D019175:DNA Methylation / Q000235:genetics; D044127:Epigenesis, Genetic / Q000235:genetics; D005060:Europe; D006801:Humans; D058990:Molecular Targeted Therapy; D011401:Promoter Regions, Genetic / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors / Q000235:genetics*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy
chemical_list: C489427:MYC protein, human; D047428:Protein Kinase Inhibitors; D016271:Proto-Oncogene Proteins c-myc; D064127:Aurora Kinases